AXLA

Axcella Therapeutics (NASDAQ:AXLA) shares are soaring in the pre-market session today on the back of positive interim data from the Phase 2b study of its AXA1125 for the treatment of NASH. Participants in the study saw clinically and statistically significant improvements and the drug continues to show a safe and well-tolerated profile. Is AXLA Stock a Good Buy? On top of the promising results, all five analysts covering the stock are unanimous in a Buy rating leading to a Strong Buy consensus rating for AXLA stock. Further the average analyst price target of $8 points to a whopping 362.43% potential upside for Axcella stock.
https://www.tipranks.com/news/axcella-nasdaqaxla-soars-on-nash-data-street-eyes-3-5x-gains?utm_source=advfn.com&utm_medium=referral